The Latest

This Week in HIV Research: From PrEP to Treatment, There's Always More to Learn

April 18, 2019: lamivudine/raltegravir for PrEP; feminizing hormone may impact PrEP efficacy; why TAF has a better renal profile than TDF; the role of internet dating in HIV incidence trends.

By Barbara Jungwirth and Myles Helfand

Results of CDC-Funded Local Projects for MSM and Transgender People Unveiled at Prevention Conference

Project PrIDE demonstration studies in New York and Houston show that properly funded and well-designed outreach programs can impact a city's ability to provide better HIV services for underserved populations.

By Sony Salzman

This Week in HIV Research: Transgender Women in the Spotlight

Black transgender women and the HIV care continuum; PrEP uptake potential among trans women; an update on U.S. mother-to-child HIV transmission; is extra measles vaccination necessary?

By Barbara Jungwirth and Myles Helfand

For Transgender Women, PrEP Is Safe to Use With Estradiol as Feminizing Hormone Therapy, Study Says

The findings mark a crucial point in the history of PrEP delivery among trans women, as they offer clarity for health care providers, PrEP outreach campaigns, and trans women using estradiol as feminizing hormone therapy.

By Arjee Javellana Restar

Access Means More Than Co-Pays: PrEP Success for Transgender Women of Color

PrEP's success should not be measured by quantity but by quality. The basic level of health care accessibility should allow people high-quality health care provided by premiere providers and frontline staff.

By Lilianna Angel Reyes

Truvada PrEP Appears to Work for Transgender Women, but Only if Used Consistently

The more than 300 transgender women in the pivotal iPrEx pre-exposure prophylaxis (PrEP) trial had similar overall HIV infection rates whether they were randomized to take tenofovir/emtricitabine (Truvada) or placebo, but those with drug levels indic...

By Liz Highleyman for

The Role of PrEP for Transgender Women in Peru

According to a mathematical model, a combination of interventions -- including PrEP -- could drastically reduce HIV infection rates in transgender women in Peru.

By Barbara Jungwirth

3 Things to Keep in Mind About Transgender (Men's) Inclusion in HIV Prevention Research

In response to mounting evidence of the prevention benefits of pre-exposure prophylaxis (PrEP) use by HIV-negative gay and bisexual men, a discussion recently emerged about the perceived exclusion of transgender men from PrEP research studies.

By Ayden Scheim for Canadian AIDS Treatment Information Exchange

From Pragmatic to Profound, It's All Powerful: Snapshots as AIDS 2014 Begins to Close

The conference, which opened with loss and determination to persevere -- begins to close, as delegates share the last round of studies, strategies and stories of struggle before returning to the comfort or challenges of home.

By JD Davids